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colostomy (DC). METHODS: Patient-level data from
1996/1997 California and Massachusetts discharge data-
bases were examined. Relevant cases, identified by unique
patient identification, ICD9 diagnosis, procedure and
E-codes were divided into the two surgical groups. Costs
(excluding physician costs) of initial hospitalization and
readmission for colostomy closure were calculated. Sta-
tistical analyses were performed using chi-square and
Wilcoxon tests for: number of colon injuries; co-existing
intra-abdominal injuries; and complications. Cost esti-
mates, adjusted for medical inflation and cost-to-charge
ratios, are reported in 1999 US $. RESULTS: Of the 597
patients identified, 489 (83%) had a PR. The mean initial
length-of-stay was longer for the colostomy group (13.5
versus 10.4 days). The mean total cost of the initial stay
was $32,800 and $46,100 for the PR and DC groups, re-
spectively. Colostomy patients were referred for home
health care (HHC) four times more often. The mean re-
admission cost for colostomy closure was $15,400, re-
sulting in a combined mean hospital cost of $61,500 for
the DC group. No significant statistical differences in
number of colon injuries, other intra-abdominal injuries
or complications were revealed. CONCLUSIONS: The
cost of managing a colon injury with a colostomy is al-
most twice as much as one managed with PR. This cost
difference estimate is conservative as it does not include
physician, HHC, colostomy care or supply costs, which
would increase the overall cost of the DC approach. Eco-
nomic, as well as clinical consequences exist regarding
choice of surgical repair.
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Purified perfluoro-n-octane (PFnO) was approved for use
as an intraoperative vitreous substitute during retinal de-
tachment surgery in 1996. This new technology is associ-
ated with improved surgical outcomes. While PFnO is
used increasingly in the hospital setting, usage in ambula-
tory surgical centers (ASC) is infrequent, likely due to
current Medicare reimbursement. Health Care Financing
Administration’s (HCFA) proposal to lower ASC reim-
bursement rates based on pre-1996 data threatens to fur-
ther discourage PFnO use. OBJECTIVE: To investigate
the economic impact of PFnO during retinal detachment
surgery, and to determine whether this impact justifies
additional ASC Medicare reimbursement. METHODS:
An economic model was developed based on retinal de-
tachment surgery success rates published in the literature
and 1997 Medicare Part B Extract and Summary System
data from HCFA. This model includes a yearly projection
from 1998–2002 to estimate HCFA costs over 5 years if
PFnO is used. HCFA’s recently proposed reimbursement
fee is used to estimate Medicare-related costs to HCFA
for retinal detachment repair using PFnO. RESULTS:
Retinal detachment surgery success rates indicate that
PFnO use is associated with 133,175 fewer retinal de-
tachment reoperations required over five years, corre-
sponding to a cost savings exceeding $268M. A recom-
mended additional reimbursement of $230.00 per surgery
would be associated with a net cost savings to HCFA of
$75.6M over five years. An additional reimbursement of
$320.30 per surgery for PFnO would be budget neutral.
CONCLUSIONS: PFnO represents a new technology as-
sociated with improved surgical outcomes and reduced
health care costs. Because current reimbursement policies
may discourage the use of PFnO in ASCs, an additional
reimbursement of $230.00 per surgery is recommended
when PFnO is used.
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The use of epoetin alpha in the community hospital has
dramatically improved patient outcomes while at the
same time has become the most expensive medication on
the hospital formulary. Significant savings can be achieved
and patient care improved by the development and im-
plementation of guidelines for the use and distribution of
epoetin alpha. OBJECTIVE: The goal of this study is to
use cost-minimization analysis to find ways the commu-
nity hospital can reduce the cost of treating patients with
epoetin alpha while at the same time develop sound
health economic policies which will insure the best possi-
ble care for their patients. To develop a multi-disciplinary
model of care which will assist the clinical pharmacist in
monitoring patients being treated with epoetin alpha.
METHODS: Data was collected pertaining to the pur-
chase, distribution, use and non-use of epoetin alpha at
John T. Mather Memorial Hospital for two one-week pe-
riods. Cost-minimization analysis was utilized to find the
least expensive method of acquisition, distribution and
dispensing of epoetin alpha. RESULTS: In the two weeks
of the study, 155 doses of epoetin alpha were dispensed
to 79 patients at a cost of $22,631.55. A total of 44 doses
were dispensed and not utilized by the patients at a cost
of $9484.80. Of the 79 patients studied, 11% of the pa-
tients had hematocrit levels that did not warrant use of
epoetin alpha and 45% of the patients showed no indi-
cated need for the drug totaling $8579.78. CONCLU-
SION: The utilization of pharmacoeconomics and clini-
cal pharmacists in the community hospital will result in
the development of health care management policies that
will not only provide better patient care, but greater eco-
nomic benefits as well.
